Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy.

PloS one - 1 Jan 2026

Ibraheem Walaa, Alsheikh Fatima, Alzain Abdulrahim A, Bhongade Bhoomendra A, Ejaz Laila, Baig Hamnah, Robinson Robert C, El-Tanani Mohamed

Abstract excerpt

BACKGROUND/OBJECTIVES: Colorectal cancer is characterized by various oncogenic mutations, with the KRAS G12D mutation being the most prevalent. The development of MRTX1133 has revitalized the KRAS direct targeting. However, colorectal cancer demonstrated intrinsic resistance to MRTX1133, primarily due to the feedback activation of the EGFR pathway. Combining KRAS G12D and EGFR inhibition has demonstrated improved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to ErbB Receptors

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 41604371
DOI: 10.1371/journal.pone.0338123
PMCID: PMC12851494

Genes

KRAS
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy.PMID 41604371Read ↗

Integrating computational chemistry and machine learning to predict KRAS mutation-induced resistanceSemantic proximity Read ↗

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C.Semantic proximity Read ↗

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.Semantic proximity Read ↗

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read ↗

Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy.Semantic proximity Read ↗

Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.Semantic proximity Read ↗

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity Read ↗

KRAS G12D can be targeted by potent salt-bridge forming inhibitorsSemantic proximity Read ↗

Identification of natural compounds targeting the KRAS G12D mutation in pancreatic cancer through integrated in silico and in vitro approaches.Semantic proximity Read ↗

Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.Semantic proximity Read ↗

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read ↗

CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.